Mar 20, 2024 Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024 Learn More
Mar 4, 2024 Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer Learn More
Feb 7, 2024 Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference Learn More